Anika Therapeutics (ANIK) Current Leases (2019 - 2026)

Anika Therapeutics (ANIK) has 8 years of Current Leases data on file, last reported at $1.9 million in Q1 2026.

• On a quarterly basis, Current Leases rose 3.63% year-over-year to $1.9 million in Q1 2026; TTM through Mar 2026 was $1.9 million, a 3.63% increase from a year earlier, with the FY2025 full-year figure at $2.1 million, up 6.99% from the prior year.
• Current Leases for Q1 2026 stood at $1.9 million, down from $2.1 million in the prior quarter.
• Over the last five years, Current Leases for ANIK reached as high as $2.3 million in Q3 2024 and fell as low as $132000.0 in Q2 2022.
• Historically, Current Leases has averaged $1.9 million across 5 years, with a median of $1.9 million in 2026.
• Across the five-year window, Current Leases jumped 1479.55% in 2023 and dropped 24.74% in 2025, its largest moves.
• Year by year, Current Leases stood at $2.1 million in 2022, then dropped by 11.87% to $1.8 million in 2023, then climbed by 4.98% to $1.9 million in 2024, then grew by 6.99% to $2.1 million in 2025, then slipped by 5.36% to $1.9 million in 2026.
• Per Business Quant data, the three most recent Current Leases figures were $1.9 million in Q1 2026, $2.1 million in Q4 2025, and $1.7 million in Q3 2025.